Treatment of Children with Mental Disorders
A booklet with answers to frequently asked questions about the treatment of mental disorders in children — includes a medications chart. (2004)
A Note to Parents
There has been public concern over reports that very young children are being prescribed psychotropic medications. The studies to date are incomplete, and much more needs to be learned about young children who are treated with medications for all kinds of illnesses. In the field of mental health, new studies are needed to tell us what the best treatments are for children with emotional and behavioral disturbances.
Children are in a state of rapid change and growth during their developmental years. Diagnosis and treatment of mental disorders must be viewed with these changes in mind. While some problems are short-lived and don’t need treatment, others are persistent and very serious, and parents should seek professional help for their children.
Not long ago, it was thought that many brain disorders such as anxiety disorders, depression, and bipolar disorder began only after childhood. We now know they can begin in early childhood. An estimated 1 in 10 children and adolescents in the United States suffers from mental illness severe enough to cause some level of impairment. Fewer than one in five of these ill children receives treatment. Perhaps the most studied, diagnosed, and treated childhood-onset mental disorder is attention deficit hyperactivity disorder (ADHD), but even with this disorder there is a need for further research in very young children.
This booklet contains answers to frequently asked questions regarding the treatment of children with mental disorders.
Questions and Answers
Q: What should I do if I am concerned about mental, behavioral, or emotional symptoms in my young child?
A: Talk to your child’s doctor. Ask questions and find out everything you can about the behavior or symptoms that worry you. Every child is different and even normal development varies from child to child. Sensory processing, language, and motor skills are developing during early childhood, as well as the ability to relate to parents and to socialize with caregivers and other children. If your child is in daycare or preschool, ask the caretaker or teacher if your child has been showing any worrisome changes in behavior, and discuss this with your child’s doctor.
Q: How do I know if my child’s problems are serious?
A: Many everyday stresses cause changes in behavior. The birth of a sibling may cause a child to temporarily act much younger. It is important to recognize such behavior changes, but also to differentiate them from signs of more serious problems. Problems deserve attention when they are severe, persistent, and impact on daily activities. Seek help for your child if you observe problems such as changes in appetite or sleep, social withdrawal, or fearfulness; behavior that seems to slip back to an earlier phase such as bed-wetting; signs of distress such as sadness or tearfulness; self-destructive behavior such as head banging; or a tendency to have frequent injuries. In addition, it is essential to review the development of your child, any important medical problem he/she might have had, family history of mental disorders, as well as physical and psychological traumas or situations that may cause stress.
Q: Whom should I consult to help my child?
A: First, consult your child’s doctor. Ask for a complete health examination of your child. Describe the behaviors that worry you. Ask whether your child needs further evaluation by a specialist in child behavioral problems. Such specialists may include psychiatrists, psychologists, social workers, and behavioral therapists. Educators may also be needed to help your child.
Q: How are mental disorders diagnosed in young children?
A: Similar to adults, disorders are diagnosed by observing signs and symptoms. Askilled professional will consider these signs and symptoms in the context of the child’sdevelopmental level, social and physical environment, and reports from parents andother caretakers or teachers, and an assessment will be made according to criteriaestablished by experts. Very young children often cannot express their thoughts andfeelings, which makes diagnosis a challenging task. The signs of a mental disorder inayoung child may be quite different from those of an older child or an adult.
Stimulant Medications
There are four stimulant medications that are approved for use in the treatment of attention deficit hyperactivity disorder (ADHD), the most common behavioral disorder of childhood. These medications have all been extensively studied and are specifically labeled for pediatric use. Children with ADHD exhibit such symptoms as short attention span, excessive activity, and impulsivity that cause substantial impairment in functioning. Stimulant medication should be prescribed only after a careful evaluation to establish the diagnosis of ADHD and to rule out other disorders or conditions. Medication treatment should be administered and monitored in the context of the overall needs of the child and family, and consideration should be given to combining it with behavioral therapy. If the child is of school age, collaboration with teachers is essential.
Antidepressant and Antianxiety Medications
These medications follow the stimulant medications in prevalence among children and adolescents. They are used for depression, a disorder recognized only in the last 20 years as a problem for children, and for anxiety disorders, including obsessive-compulsive disorder (OCD). The medications most widely prescribed for these disorders are the selective serotonin reuptake inhibitors (the SSRIs).
In the human brain, there are many “neurotransmitters” that affect the way we think, feel, and act. Three of these neurotransmitters that antidepressants influence are serotonin, dopamine, and norepinephrine. SSRIs affect mainly serotonin and have been found to be effective in treating depression and anxiety without as many side effects as some older antidepressants.
Antipsychotic Medications
These medications are used to treat children with schizophrenia, bipolar disorder, autism, Tourette’s syndrome, and severe conduct disorders. Some of the older antipsychotic medications have specific indications and dose guidelines for children. Some of the newer “atypical” antipsychotics, which have fewer side effects, are also being used for children. Such use requires close monitoring for side effects.
Mood Stabilizing Medications
These medications are used to treat bipolar disorder (manic-depressive illness). However, because there is very limited data on the safety and efficacy of most mood stabilizers in youth, treatment of children and adolescents is based mainly on experience with adults. The most typically used mood stabilizers are lithium and valproate (Depakote®), which are often very effective for controlling mania and preventing recurrences of manic and depressive episodes in adults. Research on the effectiveness of these and other medications in children and adolescents with bipolar disorder is ongoing. In addition, studies are investigating various forms of psychotherapy, including cognitive-behavioral therapy, to complement medication treatment for this illness in young people.
Effective treatment depends on appropriate diagnosis of bipolar disorder in children and adolescents. There is some evidence that using antidepressant medication to treat depression in a person who has bipolar disorder may induce manic symptoms if it is taken without a mood stabilizer. In addition, using stimulant medications to treat co-occurring ADHD or ADHD-like symptoms in a child with bipolar disorder may worsen manic symptoms. While it can be hard to determine which young patients will become manic, there is a greater likelihood among children and adolescents who have a family history of bipolar disorder. If manic symptoms develop or markedly worsen during antidepressant or stimulant use, a physician should be consulted immediately, and diagnosis and treatment for bipolar disorder should be considered.
Q: What difference does it make if a medication is specifically approved for use in children or not?
A: Approval of a medication by the FDA means that adequate data have been provided to the FDA by the drug manufacturer to show safety and efficacy for a particular therapy in a particular population. Based on the data, a label indication for the drug is established that includes proper dosage, potential side effects, and approved age. Doctors prescribe medications as they feel appropriate even if those uses are not included in the labeling. Although in some cases there is extensive clinical experience in using medications for children or adolescents, in many cases there is not. Everyone agrees that more studies in children are needed if we are to know the appropriate dosages, how a drug works in children, and what effects there are on learning and development.
Q: What does “off-label” use of a medication mean?
A: Many medications that are on the market have not been officially approved by the FDA for use in children. Treatment of children with these medications is called “off-label” use. For some medications, the off-label use is supported by data from well-conducted studies in children. For instance, some antidepressant medications have been shown to be effective in children and adolescents with depression. For other medications, there are no controlled studies in children, but only isolated clinical reports. In particular, the use of psychotropic medications in preschoolers has not been adequately studied and must be considered very carefully by balancing severity of symptoms, degree of impairment, and potential benefits and risks of treatment.
Q: Why haven’t many medications been tested in children?
A: In the past, medications were not studied in children because of ethical concerns about involving children in clinical trials. However, this created a new problem: lack of knowledge about the best treatments for children. In clinical settings where children are suffering from mental or behavioral disorders, medications are being prescribed at increasingly early ages. The FDA has been urging that products be appropriately studied in children and has offered incentives to drug manufacturers to carry out such testing. The NIH and the FDA are examining the issue of medication research in children and are developing new research approaches.
Q: Does the FDA approve medications for different age groups among children?
A: Yes. However, this is based on the data provided to the FDA by the drug manufacturer and the policies in effect at the time of approval. For example, Ritalin® is approved for children age 6 and older, whereas Dexedrine® is approved for children as young as 3. When Ritalin® was tested for efficacy by its manufacturer, only children age 6 and above were involved; therefore, age 6 was approved as the lower age limit for Ritalin®.
Q: Can events such as a death in the family, illness in a parent, onset of poverty, or divorce cause symptoms?
A: Yes. When a tragedy occurs or some extreme stress hits, every member of a family is affected, even the youngest ones. This should also be considered when evaluating mental, emotional, or behavioral symptoms in a child.
Medications Chart
| Type of Medication | Brand Name | Generic Name | Approved Age |
|---|---|---|---|
| Stimulant Medications | Adderall | amphetamines | 3 and older |
| Concerta | methylphenidate | 6 and older | |
| Cylert* | pemoline | 6 and older | |
| Dexedrine | dextroamphetamine | 3 and older | |
| Dextrostat | dextroamphetamine | 3 and older | |
| Ritalin | methylphenidate | 6 and older | |
| Antidepressant and Antianxiety Medications | Anafranil | clomipramine | 10 and older (for OCD) |
| BuSpar | buspirone | 18 and older | |
| Effexor | venlafaxine | 18 and older | |
| Luvox (SSRI) | fluvoxamine | 8 and older (for OCD) | |
| Paxil (SSRI) | paroxetine | 18 and older | |
| Prozac (SSRI) | fluoxetine | 18 and older | |
| Serzone (SSRI) | nefazodone | 18 and older | |
| Sinequan | doxepin | 12 and older | |
| Tofranil | imipramine | 6 and older (for bed-wetting) | |
| Wellbutrin | bupropion | 18 and older | |
| Zoloft (SSRI) | sertraline | 6 and older (for OCD) | |
| Antipsychotic Medications | Clozaril(atypical) | clozapine | 18 and older |
| Haldol | haloperidol | 3 and older | |
| Risperdal (atypical) | risperidone | 5 to 16 years (for irritability associated with autistic disorder); 18 and older (for schizophrenia and bipolar mania) | |
| Seroquel (atypical) | quetiapine | 18 and older | |
| (Generic Only) | thioridazine | 2 and older | |
| Zyprexa (atypical) | olanzapine | 18 and older | |
| Orap | pimozide | 12 and older (for Tourette’s syndrome). Data for age 2 and older indicate similar safety profile. | |
| Mood Stabilizing Medications | Cibalith-S | lithium citrate | 12 and older |
| Depakote | divalproex sodium | 2 and older (for seizures) | |
| Eskalith | lithium carbonate | 12 and older | |
| Lithobid | lithium carbonate | 12 and older | |
| Tegretol | carbamazepine | any age (for seizures) |
*Because of its potential for serious side effects affecting the liver, Cylert should not ordinarily be considered as first line drug therapy for ADHD.
References
1. Burns BJ, Costello EJ, Angold A, Tweed D, Stangl D, Farmer EM, Erkanli A. Data Watch: children’s mental health service use across service sectors. Health Affairs, 1995; 14(3): 147-59.
2. Coyle JT. Psychotropic drug use in very young children [editorial]. Journal of the American Medical Association, 2000; 283(8): 1059-60.
3. Physician’s Desk Reference (PDR). Montvale, NJ: Medical Economics Company, 1999.
4. Shaffer D, Fisher P, Dulcan MK, Davies M, Piacentini J, Schwab-Stone ME, Lahey BB, Bourdon K, Jensen PS, Bird HR, Canino G, Regier DA. The NIMH diagnostic interview schedule for children version 2.3 (DISC 2.3): description, acceptability, prevalence, rates, and performance in the MECA study. Journal of the Academy of Child and Adolescent Psychiatry, 1996; 35(7): 865-77.
5. Zito JM, Safer DJ, dosReis S, Gardner JF, Botes M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association, 2000; 283(8): 1025-30.
